An anti-diabetic drug (sulfonylurea glyburide) has been shown to act as an inhibitor of NLRP315, suggesting that NLRP3 inflammasome may be a promising therapeutic target in T2D clinical trials. Here, NLRP3 is linked to type 2 diabetes mellitus.